头颈癌加速再增殖的剂量依赖性:支持证据与临床意义
该研究基于7283例头颈癌患者随机试验的肿瘤控制数据,比较标准剂量非依赖性加速再增殖模型与剂量依赖性模型。剂量依赖性模型对数据的描述显著更优,并预测当前头颈癌分割方案中最后5次照射不增加肿瘤控制率,仅补偿加速再增殖。
要点
- 剂量依赖性加速再增殖模型对头颈癌随机试验数据的描述显著优于标准模型。
- 当前头颈癌分割方案中最后5次照射不增加肿瘤控制率。
- 省略最后一周5次照射可能不损害肿瘤控制且降低晚期毒性。
核心结论
- 剂量依赖性加速再增殖模型显著改善了对头颈癌大范围随机临床数据的描述。
- 该模型预测当前头颈癌分割方案中最后5次照射不增加肿瘤控制率,仅补偿加速再增殖。
- 省略最后一周5次照射可能不损害肿瘤控制率,且因总剂量降低可显著减少晚期后遗症。
研究设计与样本
- 分析头颈癌随机试验的肿瘤控制数据,共7283例患者,涵盖宽范围的剂量、时间和分割方案。
- 采用线性二次模型,分别搭配标准剂量非依赖性加速再增殖模型或剂量依赖性模型进行比较。
主要发现
- 剂量依赖性模型对广泛随机临床数据的描述显著优于标准剂量非依赖性模型。
- 该优选模型预测当前头颈癌分割方案中最后5次照射不增加肿瘤控制率,仅补偿增加的加速再增殖。
临床怎么用
- 对于当前标准分割的头颈癌放疗,可考虑省略最后一周5次照射以降低总剂量和晚期后遗症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Accelerated repopulation (AR) can compromise tumor control after conventional radiotherapy for fast-growing tumors. Standard AR models assume it begins at a fixed time, with repopulation rates independent of the number of clonogens killed. We investigate the validity and significance of an alternative model where onset-time and rate of AR depend on the number of clonogens killed, and thus on dose and dose-fractionation. MATERIALS AND METHODS: We analyzed tumor control (TCP) from randomized trials for head and neck cancer (HNC, 7283 patients), featuring wide ranges of doses, times, and fractionation-schemes. We used the linear-quadratic model with the standard dose-independent AR model, or with an alternative dose-dependent model, where AR onset and rate depend on clonogen killing. RESULTS: The alternative dose-dependent model of AR provides significantly-improved descriptions of a wide range of randomized clinical data, relative to the standard dose-independent model. This preferred model predicts that, for currently-used HNC fractionation schemes, the last 5 fractions do not increase TCP, but simply compensate for increased accelerated repopulation. CONCLUSIONS: The preferred dose-dependent AR model predicts that, for standard fractionation schemes currently used to treat HNC, the final week (5 fractions) could be eliminated without compromising TCP, but resulting in significantly decreased late sequelae due to the lower overall dose.
引用
- Shuryak I, Hall EJ, Brenner DJ, et al. Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications. Radiother Oncol. 2018. PMID: 29534828. doi:10.1016/j.radonc.2018.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。